AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial
AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial
AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.